Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Nucleoside Analogs as Anti-HBV Agents

Author(s): Xiao-Xiong Zhou and Eddy Littler

Volume 6, Issue 9, 2006

Page: [851 - 865] Pages: 15

DOI: 10.2174/156802606777303667

Price: $65

Abstract

Chronic hepatitis B virus (HBV) infection affects about 400 million people worldwide. The development of nucleoside analogs that inhibit HBV polymerase provides an important approach for treating HBV infection. The approval of lamivudine, adefovir and entecavir represents a cornerstone of hepatitis B therapy. However, the challenges from the resistance and the off-therapy viral rebound are still unmet, and there is a need of developing new therapeutic agents. This review will discuss the structure-activity relationship of the most significant anti-HBV nucleoside analogs and the latest development in the field.

Keywords: Hepatitis B virus, hepatitis, nucleoside, nucleoside phosphonate, nucleotide, lamivudine, emtricitabine, entecavir, adefovir


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy